Schaper Benz & Wise Investment Counsel Inc. WI Sells 3,338 Shares of Johnson & Johnson (NYSE:JNJ)

Schaper Benz & Wise Investment Counsel Inc. WI reduced its position in Johnson & Johnson (NYSE:JNJGet Rating) by 2.9% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 110,549 shares of the company’s stock after selling 3,338 shares during the period. Johnson & Johnson accounts for about 1.7% of Schaper Benz & Wise Investment Counsel Inc. WI’s portfolio, making the stock its 19th largest position. Schaper Benz & Wise Investment Counsel Inc. WI’s holdings in Johnson & Johnson were worth $19,593,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Family CFO Inc bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $26,000. Steward Financial Group LLC purchased a new position in shares of Johnson & Johnson in the 4th quarter valued at approximately $34,000. Joseph P. Lucia & Associates LLC purchased a new position in shares of Johnson & Johnson in the 1st quarter valued at approximately $38,000. Advocacy Wealth Management Services LLC raised its position in shares of Johnson & Johnson by 41.4% in the 1st quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company’s stock valued at $41,000 after purchasing an additional 67 shares during the last quarter. Finally, Gibson Wealth Advisors LLC purchased a new position in shares of Johnson & Johnson in the 4th quarter valued at approximately $49,000. 68.78% of the stock is currently owned by institutional investors.

Insider Activity at Johnson & Johnson

In related news, CAO Robert J. Decker sold 8,462 shares of Johnson & Johnson stock in a transaction on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the sale, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, EVP Kathryn E. Wengel sold 40,000 shares of Johnson & Johnson stock in a transaction on Friday, June 10th. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the sale, the executive vice president now owns 71,311 shares of the company’s stock, valued at approximately $12,336,803. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Robert J. Decker sold 8,462 shares of Johnson & Johnson stock in a transaction on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the completion of the sale, the chief accounting officer now directly owns 15,473 shares in the company, valued at approximately $2,785,140. The disclosure for this sale can be found here. 0.35% of the stock is owned by corporate insiders.

Analyst Ratings Changes

JNJ has been the subject of several research analyst reports. Morgan Stanley increased their price objective on shares of Johnson & Johnson from $173.00 to $174.00 and gave the company an “equal weight” rating in a research report on Friday, July 8th. Raymond James increased their price objective on shares of Johnson & Johnson from $195.00 to $196.00 and gave the company an “outperform” rating in a research report on Wednesday, April 20th. UBS Group decreased their price objective on shares of Johnson & Johnson from $185.00 to $180.00 in a research report on Thursday. Credit Suisse Group raised their price target on shares of Johnson & Johnson from $200.00 to $205.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 20th. Finally, The Goldman Sachs Group raised their price target on shares of Johnson & Johnson from $163.00 to $181.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 12th. Four equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $189.89.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $172.12 on Monday. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.39 and a quick ratio of 1.14. The firm has a market cap of $452.92 billion, a price-to-earnings ratio of 25.05, a price-to-earnings-growth ratio of 3.49 and a beta of 0.63. The company has a 50 day moving average price of $176.25 and a 200-day moving average price of $174.38. Johnson & Johnson has a 1-year low of $155.72 and a 1-year high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.57 by $0.02. The firm had revenue of $24.02 billion during the quarter, compared to analyst estimates of $23.85 billion. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.56%. The business’s quarterly revenue was up 3.0% on a year-over-year basis. During the same period in the previous year, the firm earned $2.48 EPS. Equities research analysts forecast that Johnson & Johnson will post 10.05 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 6th. Stockholders of record on Tuesday, August 23rd will be issued a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a dividend yield of 2.63%. The ex-dividend date of this dividend is Monday, August 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is 65.79%.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

See Also

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.